2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-133195
    Nefopam 13669-70-0 98%
    Nefopam (Fenazoxine) is an orally active, non-opioid and non-steroidal centrally acting analgesic agent. Nefopam blocks voltage-sensitive sodium channels (IC50=27 μM) and modulates glutamatergic transmission in rodents. Nefopam can be used in studies of neuropathic pain, anticonvulsant, as well as the prevention of postoperative shivering and hiccups.
    Nefopam
  • HY-133533
    O-2050 1883545-42-3 98%
    O-2050 is a high affinity cannabinoid CB1 receptor antagonist with a Ki of 2.5 nM. O-2050 inhibits cannabinoid CB2 receptor (Ki=0.2 nM). O-2050 can cause locomotor stimulation in mice.
    O-2050
  • HY-133596
    12,14-Dichlorodehydroabietic acid 65281-77-8 98%
    12,14-Dichlorodehydroabietic acid, a chlorinated resin acid, is a potent Ca2+-activated K+ (BK) channel opener. 12,14-Dichlorodehydroabietic acid blocks GABA-dependent chloride entry in mammalian brain and operates as a non-competitive GABAA antagonist. 12,14-Dichlorodehydroabietic acid increases cytosolic free Ca2+ and stimulates transmitter release.
    12,14-Dichlorodehydroabietic acid
  • HY-133732
    Alaproclate hydrochloride 60719-83-7 98%
    Alaproclate (GEA 654) hydrochloride is a selective and orally active serotonin re-uptake inhibitor (SSRI). Alaproclate hydrochloride also acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow.
    Alaproclate hydrochloride
  • HY-133773
    Desoxochlordiazepoxide 4393-72-0 98%
    Desoxochlordiazepoxide is a kind of benzodiazepine compound. Desoxochlordiazepoxide has anticonvulsant effect.
    Desoxochlordiazepoxide
  • HY-133797
    Cyclobenzaprine N-oxide 6682-26-4 98%
    Cyclobenzaprine N-oxide is the tertiary amine metabolite of Cyclobenzaprine (HY-B0740) in liver particles. Cyclobenzaprine is a skeletal muscle relaxant and is active on the central nervous system. The liver cytosol from liver particles has reductase activity that can reduce Cyclobenzaprine N-oxide to the corresponding amine.
    Cyclobenzaprine N-oxide
  • HY-133832
    Elopiprazole 115464-77-2 98%
    Elopiprazole can be used in study of neurological disease and SARS-CoV-2.
    Elopiprazole
  • HY-133858
    25N-NBOMe hydrochloride 1566571-65-0 98%
    25N-NBOMe hydrochloride, a 2C-N derivative, is a 5-HT2A and 5-HT2C receptors agonist with Ki values of 0.144 nM and 1.06 nM, respectively. 25N-NBOMe hydrochloride has little to no efficacy at inducing release of preloaded neurotransmitter from recombinant dopamine, serotonin and norepinephrine transporters.
    25N-NBOMe hydrochloride
  • HY-133935
    Benaxibine 27661-27-4 98%
    Benaxibine is an alkaloid belonging to the quinolone family of compounds. Benaxibine has a variety of biological activities, including anti-inflammatory, antioxidant, anti-tumor and immune-enhancing effects. Benaxibine can be used for screening and research of diseases such as inflammation and tumor.
    Benaxibine
  • HY-133956
    3-ATA 129821-08-5 98%
    3-ATA (NSC 680434) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) with neuroprotective and antitumor effects. 3-ATA can alleviate kainic acid (HY-N2309)-induced apoptosis in cerebellar granule neurons, which can be used in the study of neurodegenerative diseases.
    3-ATA
  • HY-133985
    7(Z)-Pentacosene 63623-49-4 98%
    7(Z)-Pentacosene is an aggregation pheromone of the European earwig (Forficula auricularia). 7(Z)-Pentacosene can be used in the study of insect behavior and neurobiology.
    7(Z)-Pentacosene
  • HY-134006
    Stemoninine 69772-72-1 98%
    Stemoninine is a lycoris alkaloid that can be used as an antitussive. Stemoninine has significant inhibitory activity against human acetylcholinesterase (AChE) (IC50=5.52 μM).
    Stemoninine
  • HY-134015
    7-Hydroxy-DPAT 74938-11-7 98%
    7-Hydroxy-DPAT (7-OH-DPAT) is a selective D3 dopamine receptor agonist. 7-Hydroxy-DPAT exhibits significant pharmacological activity in modulating locomotor behavior and dopamine metabolism within the brain. 7-Hydroxy-DPAT can be used for the research of neurological disease .
    7-Hydroxy-DPAT
  • HY-13409B
    SB 242084 monohydrochloride 1260505-34-7 98%
    SB 242084 monohydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 monohydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 monohydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage.
    SB 242084 monohydrochloride
  • HY-134189
    EST73502 1838622-25-5 98%
    EST73502 is a selective, orally active and blood-brain barrier (BBB) penetrant dual μ-opioid receptor (MOR) agonist and σ1 receptor (σ1R) antagonist, with Kis of 64 nM and 118 nM for MOR and σ1R, respectively. EST73502 has antinociceptive activity.
    EST73502
  • HY-134264
    8-Br-2'-O-Me-cAMP 612513-13-0 98%
    8-Br-2'-O-Me-cAMP is an analogue of the signal molecule cyclic AMP (cAMP). 8-Br-2'-O-Me-cAMP is an agonist of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP do. 8-Br-2'-O-Me-cAMP can be used in cardiovascular disease research.
    8-Br-2'-O-Me-cAMP
  • HY-134361
    ATP-γ-S tetrasodium 88453-52-5 98%
    ATP-γ-S (tetrasodium) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATP-γ-S (tetrasodium) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATP-γ-S (tetrasodium) is active in ATP hydrolysis.
    ATP-γ-S tetrasodium
  • HY-134398
    Kinetin triphosphate 1450894-16-2 98%
    Kinetin triphosphate(6-Fu-ATP; KTP) is an ATP analogue that regulates or enhances kinase function with higher catalytic efficiency than its endogenous substrate, ATP. Kinetin triphosphate can be used in Parkinson's disease research.
    Kinetin triphosphate
  • HY-134483
    5-HT7/5-HT2A receptor antagonist 1 851375-22-9 98%
    5-HT7/5-HT2A receptor antagonist 1 is a high-affinity, orally active, brain-penetrant 5-HT7 and 5-HT2A receptor ligand having a pKi = 8.1 at both receptors. 5-HT7/5-HT2A receptor antagonist 1 behaves as an antagonist in an in vitro functional assay for 5-HT2A and as an inverse agonist in an in vitro functional assay for 5-HT7. 5-HT7/5-HT2A receptor antagonist 1 blockade of 5-Carboxamidotryptamine (5-CT) (HY-135555) induced hypothermia in rats, and blockade of 2,5-dimethoxy-4-iodoamphetamine (DOI) induced head-twitches in mice. 5-HT7/5-HT2A receptor antagonist 1 occupied 5-HT2A receptor binding sites in the frontal cortex of the rat brain. 5-HT7/5-HT2A receptor antagonist 1 can be used for the study of Neurological diseases.
    5-HT7/5-HT2A receptor antagonist 1
  • HY-134562
    PF-06371900 1622291-81-9 98%
    PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor.
    PF-06371900
Cat. No. Product Name / Synonyms Application Reactivity